An important companion diagnostic marker for NSCLC
ALK (anaplastic lymphoma kinase) is also known as CD246, is a kinase receptor. ALK came into spot light when it is discovered that its translocation, such as EML4-ALK, creates a driver oncogenic gene in non-small cell lung cancer (NSCLC). A small percentage of NSCLC patients carry EML4-ALK translocation or its variants, which product oncogenic fusion protein.
Screening for this fusion gene in NSCLC is important, as "ALK-positive" tumors are highly sensitive to therapy with ALK-targeted inhibitors, such as Crizotinib. ALK translocation is detected by FISH (gold standard), IHC and RT-PCR. For the IHC diagnosis, it is a pivotal to use a highly sensitive antibody as the level of ALK expression is low in NSCLC samples.
- ALK in Scientific Publications
- ALK in Pharma/Biotech
- ALK in Translational Research
- ALK in Clinical Trial
- ALK in News
Recommended ALK products
|UM800118||• ALK mouse monoclonal antibody, clone OTIA4, 100ul|
The use of this Antibody has been cited in the following citations:
Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study, Qiushi Wang, Lianhua Zhao, Xin Yang, Shirong Wei, Ying Zeng, Chengyi Mao, Li Lin,Ping Fu, Liang Lyu, Zengpeng Li, Hualiang Xiao, Lung Cancer Feb 2016 [ALK]
NordiQC Immunohistochemistry Quality Control Run 45 2015 on Lung Anaplastic Lymphoma Kinase (Lu-ALK), Nordi QC Team, NordiQC assessment Run 45 on ALK [ALK]
Inflammatory myofibroblastic tumour of the bladder in children: A review, Collin, M;Charles, A;Barker, A;Khosa, J;Samnakay, N;, J Pediatr Urol Apr 2015 [ALK]
A Novel, Highly Sensitive ALK Antibody 1A4 Facilitates Effective Screening for ALK Rearrangements in Lung Adenocarcinomas by Standard Immunohistochemistry, Gruber K, KohlhÃ¤ufl M, Friedel G, Ott G, Kalla C., J Thorac Oncol. 2015 Apr;10(4):713-6 [ALK]
Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy, Wang, Q;He, Y;Yang, X;Wang, Y;Xiao, H;, BMC Pulm Med Jun 2014 [ALK]
TKI Sensitivity Patterns of Novel Kinase-domain Mutations Suggest
Therapeutic Opportunities for Patients with Resistant ALK+ Tumors,
Oncotarget, Mar 2016
- Novartis (Ceritinib)
- Pfizer (Crizotinib )
- Hoffmann-La Roche (Alectinib)
- Abbott (FISH, FDA Approved in USA)
- Vantana (IHC, Approved in China and EU)
Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases, Cancer Research, Mar 2016
- Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients (Enrolling by invitation)
- Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa (Recurring)
March 14 2016, Ceritinib Produces Durable Whole-body Responses in NSCLC
ALK-rearranged NSCLC is sensitive to ALK inhibitors such as crizotinib, but resistance frequently develops, often with metastases to the brain. Ceritinib is a more potent ALK inhibitor than crizotinib in vitro, crosses the blood–brain barrier in vivo, and shows clinical responses in patients with crizotinib-resistant disease.
March 11, 2016, FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer
The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.